For more information on trials listed below, or to learn about other available opportunities to participate in research studies, call the NIH Clinical Center Office of Patient Recruitment 1- 866-444-2214, TTY: 1-866-411-1010. Or email prpl@cc.nih.gov. Se habla español. For those callers who are deaf, hard-of-hearing, deafblind, or speech impaired, the Federal Relay Service provides free telecommunications relay services.
NIDDK researchers seek healthy volunteers (18-45 years old) to participate in a study investigating how dopamine affects body weight and eating behavior. Participants must be able to visit the Clinical Center for 5 consecutive days to pick up food and then have a 5-day inpatient stay. Refer to Study #18-DK-0132.
NIAID researchers seek healthy children, 2 and older with NO history of food allergy, asthma, or eczema to participate in a study. Researchers are comparing information from children with and without food allergies to better understand how food allergies affect development and health. Compensation is provided. Refer to Study #15-I-0162.
Do you or someone you know have germline RUNX1 mutations? Researchers at the National Human Genome Research Institute are conducting a study to better understand the disease progression and underlying mechanisms, which will lead to better clinical management and development of new therapies. Participation in the study will be at no cost to you. Travel may be provided. Refer to Study #19-HG-0059.
Do you or someone you know have mild to moderate psoriasis? Researchers at the NIH Clinical Center are testing a form of vitamin B3 dietary supplement to help improve the immune system function in the blood and skin of people with mild to moderate psoriasis. Treatments and research procedures are provided at no cost. Refer to Study #20-H-0044.
Have you been diagnosed with COVID-19 in the past 5 days? Then you may be able to participate in a National Institute of Allergy and Infectious Diseases. This study will help researchers determine the safety and effectiveness of the experimental drug IL-7 in helping the immune system prevent serious complications from COVID19. Treatments and research procedures are provided at no cost. Refer to Study #20-I-0140.
NHLBI researchers, in collaboration with Inova Health System, have opened enrollment of a new clinical study in hospitalized COVID-19 patients. The study will evaluate the drug fostamatinib for the treatment of COVID-19. If you are COVID-19 positive and between the ages of 18 to 90 years, you may be eligible. Refer to Study #000110.
- Submitted by the NIH Clinical Center Office of Patient Recruitment